Friday, August 2, 2013

India board revokes GSK patent on breast cancer drug Tykerb

Related News

  • UPDATE 1-US ITC delays word on whether Samsung infringes Apple's patents

    Thu, Aug 1 2013

  • India's Strides responds to FDA, continues shipments to U.S

    Wed, Jul 31 2013

  • Glaxo warns China corruption scandal will hit business

    Wed, Jul 24 2013

  • GSK used travel agencies for China bribes: police

    Mon, Jul 15 2013

  • China says GSK execs confess to bribery and tax crimes

    Thu, Jul 11 2013

Analysis & Opinion

  • Apple asks Obama to take a stand on injunctions and essential patents
  • In Pakistan, Kashmir becomes a new rallying cry
A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

A no entry sign is pictured outside the GlaxoSmithKline building in Hounslow, west London June 18, 2013.

Credit: Reuters/Luke MacGregor

MUMBAI | Fri Aug 2, 2013 1:40am EDT

MUMBAI (Reuters) - India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.

However, the Intellectual Property Appellate Board (IPAB) upheld a patent granted to the original compound, or active pharmaceutical ingredient, citing innovative merit.

Fresenius Kabi Oncology, the Indian unit of German healthcare group Fresenius SE, had challenged patents granted for both the original molecule and it's marketed version Tykerb, saying both molecules lacked innovation.

"We are studying the IPAB's decision but maintain our belief in the inventiveness of the lapatinib ditosylate salt and will consider the possibility of taking further steps before the appropriate authorities to validate this," the Indian unit of UK-based GSK said in an email to Reuters on Friday.

The IPAB orders for both the patent disputes were uploaded on its website late on Thursday.

(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


Source : http://feeds.reuters.com/~r/reuters/healthNews/~3/81iZfcq3brc/story01.htm

Posted by at